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 The use of temocillin (TEM) is 
increasing in serious infections caused 
by Enterobacteriaceae, including 
extended-spectrum β-lactamases 
(ESBL), as an alternative to 
carbapenems (1-5).  
 Therefore, accuracy of in vitro minimal 
inhibitory concentration (MIC) values is 
of high importance in an era of 
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 100 isolates of Enterobacteriaceae were collected from respiratory samples isolated 
from ICU patients.  
 MICs of temocillin were determined in parallel by 3 methods:  
  E-test® (Biomérieux, France) (A) 
  Vitek2® (Biomérieux, France) (B) 







 Since no EUCAST or CLSI breakpoint guidelines exist at this time, susceptibility to temocillin 
was determined according to breakpoints provided by BSAC (British Society for Antimicrobial 
Chemotherapy) (6) (S: MIC ≤ 8 mg/L; R: MIC > 8 mg/L). 
 Evaluation of categorical agreement (CA), essential agreement (EA), very major errors 
(VME) and major errors (ME), as defined in Cumitech 31A (7) .  
  The production of ESBL or carbapenemase was screened according to the antibiotic 
susceptibility profile.  
 ESBL expression was confirmed by the double-disc synergy test.  
 Carbapenemase production was established by a colorimetric test detecting the 
carbapenem hydrolysis or using an immunochromatographic assay.  
 
 100 Enterobacteriaceae isolates were collected: 
 Klebsiella pneumoniae (KP) (34%), Escherichia coli (EC) (23%), Serratia spp. (18%), others (25%). 
  35 were ESBL-producers; 13 were carbapenemase-producers. 









 Performances per species were very different as shown in figure 1 for K.pneumoniae and E.coli   
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• To perform and compare two antimicrobial 
susceptibility testing (AST) methods used 
routinely in many laboratories: 
• Vitek2®, bioMérieux France 
• E-test®, bioMérieux France 
 for determination of TEM MICs with a 
reference broth microdilution (BMD) 
method.  
• To evaluate which method is reliable to 
determine TEM MICs. 
 Compared to BMD, essential agreements are above 90%, as recommended by Cumitech 
31A, for both E-test® and Vitek2®.   
 Results for categorical agreement are, for both methods, beyond 90% (not acceptable 
Cumitech 31A), but this can be explained by BSAC breakpoints (no “intermediate” category). 
 When taking the adapted definition of VME and ME with MIC > ± 1 twofold dilution,  
 Vitek2® still seems to overestimate sensitivity (with VME rate of 7,3%)  
 while E-test® seems to overestimate resistance (with ME rate of 6,8%). 
 Looking at the species level, this is essentially the case for E.coli. 
 The tested MIC range with Vitek2® is limited (≤4 to ≥32 mg/L). 
 When the use of TEM is considered by the clinician, we would recommend to control 
TEM MIC at least with an E-test®, or, even better, by BMD, especially for E.coli.  
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Table2 : Overall results for agreements, major and very major errors between methods. 
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Figure 1 : Concordant  and discordant results for K.pneumoniae (KP) and E.coli (EC) between methods 
Table1 : Rates of temocilline Resistance (BMD)   














14 (41%)    
6 (26%) 
14 (78%) 
  7 (28%) 
Overall 100 59 41 
